The Crux of Medtech

Raymond Cohen has spent 40+ years in medtech, never at a big company but always building. After taking Axonics from whiteboard to $500M in revenue and a Boston Scientific exit, he's now chairman of multiple high-growth ventures.In this episode, he breaks down what actually makes a company acquirable, why founders need to get over their fear of dilution, and the immigrant work ethic that's driven his entire career.Key Topics:Why Boston Scientific is outpacing every other strategic acquirer right nowThe "go big or go home" fundraising philosophy behind Spyro Medical's $67M Series AWhat "having the goods" actually means and why most founders don't know if they have themRaymond's criteria for joining a board: clinical problem, addressable market, and the right peopleHow LSI is filling the gap JP Morgan left for private medtech companiesRelated Insights:Neuromodulation as a pharmaceutical replacement: the Spyro asthma thesisCuffless ambulatory blood pressure monitoring and the BioBeat opportunityWhy the best people won't work for paper and how to structure equity properlyThe "tone from the top" principle and cutting underperformers earlyCore Challenges:Founders are paralysed by dilution fear, leading to undercapitalisation and slow execution. Raymonds's view: sell 85% on day one if that's what it takes to win.Too many startups pursue incremental innovation or enter crowded markets "the fifth person in a four-man race."Strategic acquirers beyond Boston Scientific have been passive, limiting exit options and slowing capital recycling in the ecosystem.🎧 Tune in now to hear how a 40-year medtech veteran thinks about building, buying, and betting big.

John Murphy left a corporate COO role to become employee number one at Virtual Incision then spent the next 14 years building MIRA, the world's first miniaturised soft tissue surgical robot.The pitch? A little robot on the inside, instead of a big one reaching in from the outside. The journey included five alpha iterations, a 30,000-page FDA de novo submission, remote surgery experiments from the International Space Station, and raising every dollar from Midwest investors after getting zero interest from Boston or Silicon Valley.Now advising the next generation of medtech founders, John shares the tactical, financial, and personal lessons from one of surgical robotics' longest development cycles.Key Topics:Why miniaturised surgical robotics could reshape remote and rural surgeryBreaking a 14-year R&D journey into financeable, executable chunksThe ISS experiment: remote surgery from 250 miles above EarthWhy Midwest investors backed Virtual Incision when the coasts wouldn'tRelated Insights:Medical devices is harder than aerospace, bio, and every other industry John's worked inThe "nuclear winter" of medtech financing and signs of a thawHow to think about seed through Series D as clinical and regulatory milestonesCore Challenges:Financing cycles in medtech often outlast VC fund timelines, founders must align milestones with capital strategyDifferentiation is non-negotiable: "There's 30 me-too Da Vinci players, Gary and Dave are going to win that oneThe personal toll of being a startup CEO is underestimated, founders need support beyond tactics and strategy🎧 Tune in now for hard-won lessons on building breakthrough surgical robotics, from first prototype to FDA clearance and beyond.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠⁠⁠⁠

In this episode of the Crux of Cardio, host Jordan Bergen sits down with Filip Peters, Co-founder and CEO of Acorai, to unpack how his team is building a non-invasive device that reads the pressures inside the heart, using machine learning inspired by oil and gas diagnostics.Filip shared the full founder journey: from garage prototypes in Sweden through COVID, to a 1,600-patient study across six countries and FDA Breakthrough Device designation.He explained why Acorai chose to focus on the hospitalised heart failure workflow over remote monitoring, and broke down the economics that make every heart failure admission a loss for US hospitals.Filip also discussed the challenges of fundraising in today's market, navigating EU MDR as an AI-enabled device, and his advice for cardiovascular founders on staying in "science project mode" for as long as possible.Key Topics:The transition from finance and ML into medtech entrepreneurshipHow non-invasive haemodynamic monitoring works and why it mattersInpatient vs. remote monitoring, why Acorai chose the hospital workflowThe economics of heart failure admissions and the 20x ROI caseNavigating FDA Breakthrough Device designation and the TAP Pilot programmeEU MDR challenges for AI-enabled medical devicesFundraising strategy – raising over $50M and the role of strategic investorsGo-to-market: selling directly to US hospital operational expense budgetsRelated Insights:Cross-industry inspiration: applying signal detection from oil & gas and engine diagnostics to cardiac dataThe "gold standard" problem: inherent measurement error in right heart catheterisation and what it means for AI validationWhy clinical workflow friction kills more medtech products than bad technologyHealth system venture funds as an emerging capital source for cardiovascular startupsThe value of the Cedars-Sinai Accelerator and EIC Accelerator for European foundersCore Challenges:Current non-invasive tools for estimating cardiac pressures (echo, biomarkers, X-ray) are subjective, often lagging, and vary significantly between clinicians – leading to suboptimal therapy decisions and premature discharge of heart failure patients with residual congestion.Acorai has developed a non-invasive, ML-powered sensing platform that measures both left-sided and right-sided cardiac pressures, giving clinicians a repeatable, operator-independent haemodynamic assessment, targeting better decongestion, shorter length of stay, and lower readmission rates.Tune in now to hear how Acorai is turning oil rig science into the next vital sign for heart failure management.

Alan Cohen has built companies, sold companies, started a price war between tech giants and now invests in what he calls "tech med" at DCVC, a $4.5bn deep-tech fund.The distinction matters: tech med starts with data and computational methods, not hardware. In this conversation, Alan unpacks the investments that excite him, from real-time surgical guidance to AI-powered ultrasound and the pitches that don't make the cut.He and Henry dig into hospital bottlenecks, the promise and peril of Health GPT, and his vision for a future where every treatment is personalised to a "circle of one."Key Topics:The distinction between "med tech" and "tech med"  and why it mattersHow computer vision, autonomous vehicle tech, and AI are entering the operating roomWhat DCVC looks for when investing in healthcare startupsThe "circle of one" vision for personalised therapiesWhy data strategy must be foundational, not an afterthoughtRelated Insights:The real bottleneck in hospital systems isn't technology it's workflow and staffingLLMs like Health GPT have promise, but also serious risks for untrained usersSurgeons and specialists are the scarcest resource tech should augment, not replaceCore Challenges:Healthcare costs are reaching unsustainable proportions, forcing new thinkingPersonnel shortages mean hospitals can't scale with demandSwitching behaviour in medicine is slow  new entrants need a 10x improvement to break through🎧 Tune in now to hear how one of Silicon Valley's sharpest deep-tech investors sees the future of surgical robotics, AI diagnostics, and the quantified self.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠⁠⁠⁠

In this episode of The Crux of MedTech, host Henry Norton sits down with Andrew Glass, CEO of Vivasure Medical, fresh off announcing the company's acquisition by Haemonetics Corporation.Andrew shares the full journey, from his early days in drug-eluting stents at Guidant (later Abbott), to running a $10M sales territory, to making equity investments at Abbott Ventures, and finally taking the leap to lead an Irish medtech startup through a US pivotal trial and strategic exit.He discusses what it was really like to join a company with two months of cash, why products are never perfect the first time, and the best advice he ever ignored.Andrew also reveals the hard-won leadership lesson his mentor gave him: "Don't be a jerk."Key Topics:The journey from big pharma to startup CEOHow strategic investors evaluate medtech acquisitionsRunning US pivotal trials and navigating FDA/CMS challengesManaging founder dynamics when you're the incoming CEOBuilding toward acquisition with option agreementsRelated Insights:Why sales experience is essential for medtech leadersThe value of keeping talent when boards say cutHow timing and strategic fit drive acquisition outcomesLessons from raising Series D in a difficult funding environmentCore Challenges:Joining a startup only to discover there's two months of cash left and having to raise immediately while fixing product issues the board hadn't disclosed.Navigating CMS approval delays that pushed trial timelines out by 9-12 months, requiring constant execution while waiting for the acquirer's readiness.🎧 Tune in now for an unfiltered look at what it really takes to lead a medtech startup to exit.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode, Henry Norton sits down with Mark Tapsak, Chief Science Officer at Glucotrack and one of Dexcom's earliest employees.Mark Tapsak left Medtronic for a "crazy startup" called Dexcom after seeing data so compelling he couldn't say no. Two decades later, he's back in the CGM game as Chief Science Officer at Glucotrack, working on a 3-year implantable sensor that lives in the bloodstream.Key Topics:Mark's path from blue-collar Minnesota to polymer chemistry PhDThe founding days of Dexcom and the "three fathers" of CGM (Goff, Updike, Heller)Why early CGM struggled to convince endocrinologists of continuous data's valueDexcom's pivot from implantable to short-term sensorsGlucotrack's evolution from non-invasive ear clip to intravascular 3-year sensorCurrent trial progress in Brazil and Australia, and the path to US IDERelated Insights:Why implanting devices in the body is "harder than going to the moon"The business case for long-term implantables vs. wearablesHow the immune response creates a "sleep period" that tanks glucose signalsWhy timing and market readiness matter as much as technologyCore Challenges:Early CGM implantables worked in only ~50% of patients, forcing a pivot to wearables and delaying long-term solutions by decades.Glucotrack is now targeting a 3-year intravascular sensor that bypasses the aggressive subcutaneous immune response, with US trials expected in 2026.🎧 Tune in now to hear how CGM went from academic curiosity to medical device success story, and what comes next.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode of The Crux of Cardio, host Jordan Burgin sits down with Oliver Piepenstock, CEO and co-founder of Berlin-based Noah Labs, to explore how voice biomarkers could transform the way we detect and manage heart failure.Oliver shares the journey from a quant finance career to founding a company that uses AI to hear what the human ear cannot, subtle changes in voice that signal worsening heart failure up to three weeks before hospitalisation. He discusses pitching Mayo Clinic with almost no money left, why clinical evidence beats everything, and how radical transparency shapes Noah Labs' culture as they pursue dual FDA and MDR clearance.Key Topics:How voice analysis can detect worsening heart failure 2–3 weeks before hospitalisationWhy the current standard of care (weight scales) falls shortThe founding story: from Entrepreneur First to Mayo ClinicPursuing FDA and MDR clearance simultaneouslyCombining venture funding with non-dilutive grantsRelated Insights:How AI adoption differs in regulated vs. unregulated healthcareThe advantage of centralised FDA expertise over fragmented European notified bodiesWhy algorithm performance will be the deciding factor in market adoptionCore Challenges:Heart failure is the number one hospital admission reason in the elderly and the top cost driver for health insurers globally — yet detection still relies on weight scales that catch deterioration only days out, often too late to intervene effectively.Noah Labs has developed voice biomarker technology achieving close to 90% accuracy in clinical trials, giving clinicians enough lead time to adjust medication remotely and prevent hospitalisation.🎧 Tune in now to discover how your voice could become the next vital sign in cardiac care.

In this episode, Henry Norton sits down with Robert Kieval, CEO of Arctx Medical Inc, to talk about a condition that sends 300,000 Americans to the ER every year with no approved treatment options waiting for them.Robert shares how Arctx is developing a deceptively simple solution: a cooling catheter that targets pancreatic inflammation from inside the stomach. He also opens up about the hard lessons from his previous venture, including why he wishes he'd hired a marketing lead much earlier.Key Topics:- How Arctx's gastric cooling catheter targets pancreatic inflammation- The regulatory pathway: 510(k) clearance for temperature management, de novo for pancreatitis- Designing a 200-patient randomised controlled trial with FDA IDE approval- Why market development and reimbursement strategy need to start earlyRelated Insights:- The importance of building clinical champions before commercialisation- Why new technologies must fit into existing clinical workflows to gain adoption- Navigating the current medtech funding environmentCore Challenges:- Acute pancreatitis affects 300,000 US patients annually with no targeted therapies only supportive care- Arctx's cooling catheter aims to reduce inflammation, shorten hospital stays, and become a new first-line treatment option🎧 Tune in now to hear how Arctx is turning cooling into a therapeutic platform.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠⁠⁠

In this episode of the Cruxx of MedTech podcast, host Henry Norton sits down with Ananth Ravi, founder of MOLLI Surgical and former medical physicist at the University of Toronto, to unpack the full journey from hospital research lab to acquisition by Stryker.Ananth shared the origin story behind MOLLI, a GPS-guided surgical system that replaced painful wire localisation with a tiny radioactive seed and sub-millimeter precision tracking. What started as a side project became a commercial product after inbound interest from physicians made it clear he had something worth pursuing.He discussed the challenges of spinning technology out of an academic institution, navigating FDA clearance with no regulatory background, and rebuilding a sales organisation after a painful first attempt.Ananth also opened up about the acquisition process itself: why Stryker's BD team stood out by actually showing up to watch cases in the OR, how he managed a bittersweet decision with his co-founder and investors, and what it felt like to communicate the news to a team facing uncertain futures.Key Topics:Ananth's path from medical physicist to medtech founderSpinning IP out of Sunnybrook and structuring university partnershipsNavigating FDA submissions as a first-time founderRestructuring a failing sales org around outcomes, not activityWhat made Stryker's BD approach different from other acquirersManaging team communication during an acquisitionFinding purpose and pace after a successful exitRelated Insights:The "regret framework" for making high-stakes founder decisionsWhy one cornerstone investor beats a crowded cap tableThe case against putting strategics on your cap table too earlyConsultants should check your work, not do it for youBuilding for profitability gives you optionality over building for exitCore Challenges:MOLLI replaced a painful, time-consuming wire localisation procedure with a tiny implantable marker and a digital GPS system, improving precision, patient experience, and hospital throughput. Scaling that technology required learning FDA submissions from scratch, restructuring a sales team mid-flight, and building a culture where smart people were trusted to make mistakes and learn fast.Founders face pressure to optimise for exit, but Ananth and his team built for profitability and optionality, which ultimately made the Stryker acquisition possible on their terms. For founders weighing similar decisions, his advice: keep talking to strategics, stay authentic about your limitations, and remember that the team who shows up and watches cases is the one who truly understands your value.🎧 Tune in now to hear how one founder went from tenured professor to Stryker acquisition, and why he's already back building again.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠⁠

In this Crux of Medtech crossover with the new Crux of Cardio series, Jordan and Henry sit down with Jack, his wife and caregiver Rocky, and SynCardia CEO Patrick Schnegelsberg to explore what a total artificial heart really means at the bedside and in the boardroom.Key Topics- Jack’s journey from misdiagnosis to ejection fraction of five to ten percent- ICU course, ECMO, cardiac arrest and the decision point for total artificial heart- Rocky’s lived reality as caregiver through transplant listing and repeated setbacks- How SynCardia’s pneumatic total artificial heart works as a bridge to transplant- Patient selection trade-offs between LVADs, ECMO, bivads and total artificial heart- Why SynCardia is now pursuing a fully implantable “Emperor” artificial heart platformRelated Insights- Emotional and cognitive load when a clinician becomes a critical care patient- The impact of early education and MCS teams on acceptance of advanced devices- How device simplicity and Frank–Starling physiology shape SynCardia’s design choices- Awareness gaps among cardiology and surgical teams around total artificial heart options- The role of transplant center experience and volume in total artificial heart outcomes- Long-term vision for artificial hearts as a true alternative to donor transplantation.Core Challenges- Recognising when a patient has moved beyond LVAD and inotrope support- Balancing end-organ failure risk against surgical risk and infection concerns- Managing caregiver stress during long ICU stays and on–off transplant listing- Overcoming historical perceptions and “old tech” stigma around artificial hearts- Funding and scaling class III cardiovascular hardware in a niche but severe populationTune in now to hear how total artificial hearts are reshaping advanced heart failure care, from one family’s story at the bedside to SynCardia’s plans for fully implantable devices.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠

In this episode of the Crux of Medtech Henry is joined by Thomas Looby, CEO of Conavi Medical.Thomas breaks down why combining IVUS + OCT in a single catheter could change coronary interventions and how the team is pacing toward a Q3 2025 510(k) with a measured “crawl, walk, run” launch plan.Expect candid insight on evidence, pricing, commercialisation, and strategic exit logicKey TopicsThe unmet need in PCI imaging and why single-modality tools leave blind spots.Engineering IVUS + OCT into one catheter and testing lessons from v1 to next-gen.Clinical evidence momentum: meta-analysis signals ~46% reduction in post-procedure mortality and ~52% less stent thrombosis.Regulatory path: pre-sub complete; targeting a Q3 2025 510(k).Commercial strategy: price-neutral entry, razor/razor-blade model, and a staged hospital rollout.Capital story: public listing via Titan assets and a $20M raise led largely by U.S. investors.Exit thinking: platform fit with strategics that currently have either IVUS or OCT Kanavi holds both.Related InsightsMission-driven teams as a magnet for top engineers and why it mattered here.Don’t over-index on KOLs: early adopters forgive product “sins” that mainstream users won’t.Market development should run in parallel with R&D, not after it.Canada-born tech, U.S.-centric commercialisation and how ecosystems and manufacturing partners align.Core ChallengesDriving COGS down to single-modality parity at volume (supply chain, manufacturing).Building broad market awareness beyond early KOL enthusiasm.Navigating regulatory milestones cleanly to stay on a Q3 2025 filing cadence.Competing with entrenched portfolios (Abbott, Philips, Boston) that bundle cath lab solutions.Tune in now to learn how dual-modality imaging could reset outcomes, economics, and adoption in the cath lab.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠

This episode of the Crux of Medtech features Sabine Bois, the former CEO of Occlutech.Sabine is a medtech leader whose career spans founding startups, steering a company through bankruptcy, driving IPO prep, and ultimately leading as CEO.Her story is raw, unfiltered, and filled with lessons about resilience, leadership, and navigating the brutal realities of medtech.Key Topics:Sabine’s leap from small-town Germany to founding her first medtech startupNavigating bankruptcy and rebuilding into a successful acquisitionThe commercial lessons that reshaped her career trajectoryTransition from CFO to CEO at Occlutech during global litigation and IPO prepThe turbulence behind IPO readiness, audits, and roadshowsWhy passion and relentlessness matter more than resourcesRelated Insights:Failure wasn’t an option for the Wright brothers or for startupsThe CEO’s ability to adapt their pitch can make or break fundingTiming and market cycles are often as critical as technologyStrategics are approachable but require careful balance in what you shareCore Challenges:Surviving insolvency while protecting IP and technologyLearning that a CEO’s first responsibility is revenue, not adminFacing last-minute IPO derailments and high-stakes investor negotiationsAdjusting from European regulatory norms to the strict demands of the FDARaising funds in today’s tougher, profitability-driven investor landscapeTune in now to hear Sabine’s unfiltered journey through medtech’s toughest challenges and what it really takes to lead with resilience.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠

In this episode, Henry Norton speaks with Adrian Mendes, CEO of Perimeter, a company using AI and optical imaging to tackle one of cancer surgery’s biggest problems: re operationsAdrian shares his journey from Silicon Valley tech to medtech, and unpacks how Perimeter is using real-time imaging and machine learning to give surgeons confidence they’ve removed all the cancer the first time.They discuss the challenges of moving fast in healthcare, the value of proprietary data in AI, and how Perimeter is building for scale with a clear commercial and clinical roadmap.Key Topics:Why reoperations are such a huge problem in cancer careHow OCT and AI work together during surgeryThe culture problem slowing down medtech innovationWhat sets “real” AI apart from buzzword AICommercial rollout plans and how they’re scalingThe long-term vision to expand beyond breast cancerRelated Insights:“Clear margins” are one of the biggest unmet needs in cancer surgeryAI in healthcare is only useful if it's usable surgeon workflow mattersProprietary data is more defensible than algorithms aloneCore Challenges:Healthcare’s cautious culture often slows meaningful innovationMany “AI” medtech products are just marketingCommercial scale is hard when you’re building from a startup base🎧 Tune in now to hear how Perimeter is building medtech that actually makes surgery smarter.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠⁠

Why are so few patients accessing the care they need when the tech is already here? In this episode, Henry Norton sits down with David Pettigrew CEO at my mhealth to unpack the real reasons digital health tools succeed or fail.From overlooked rehabilitation gaps to the power of patient-first design, this conversation spotlights how we can actually get medtech into the hands of the people who need it most.David shares his career pivot from corporate dream job to healthtech entrepreneur, and what it’s really like building products that serve thousands of patients. You’ll hear why uptake often has nothing to do with clinical data… and everything to do with how a product makes someone feel. Key TopicsWhy David left a “dream job” for a mission-driven startupHow digital health tools can close the rehab gapWhat makes an app truly “sticky” for usersThe business model tensions slowing down innovationLessons from working directly with patients, not just cliniciansRelated InsightsSimplicity drives adoption more than clinical complexityPatient awareness is often the biggest bottleneckScaling isn’t just about funding — it’s about access and trust Core ChallengesOnly 3% of patients in the U.S. get the rehab they needTraditional care pathways don’t scale to meet demandMany digital tools fail due to poor design and awarenessThe Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠⁠KUKA⁠⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠⁠

In this episode, your host, Henry Norton, is joined by Hannah Claridge, the Head of Neurotechnology at TTP, to talk about the incredible advancements that are being made to treat neurological conditions. Hannah points out how complex the brain and nervous systems are, with both relying on intricate connections. She also explores the new technologies that are being developed to treat nervous disorders, such as spinal cord stimulation. She also compared neurotechnologies to pharmaceuticals, highlighting the parallels and differences in how they interact with the body. Hannah also suggested that neurotherapy will be key to the advancement of treatments for conditions like depression, due to their ability to provide targeted and long-term relief of symptoms. Cybersecurity is also a major concern for neurotechnology, as any malfunction or deliberate interference could have serious ramifications for patients. Key Topics: Hannah’s current role at TTP Recent innovations in neurotechnology Policy and ethics in neurotechBarriers to market adoption Moving patient stories Related Insights: Humans use far more than 10% of the brain - this was debunked during a conversation about brain plasticity There are significant barriers to market adoption for neurosurgery, such as a lack of awareness and understanding, even among surgeons. Neurotech’s impact on patients cannot be understated, as so many conditions are currently untreatable with other intervention methods. Core Challenges:Anything that interacts with the brain in a way that changes its fundamental functions comes with huge ethical concerns and a need for heightened patient understanding and clear consent. Neurotechnology can provide relief for chronic conditions, such as long-term pain relief and the alleviation of depressive symptoms, making it a game-changing device in several areas. The challenges when it comes to developing a new neurotech product from being intuitive to miniaturisation.Tune in now to find out how neurotechnology will change healthcare for the better. The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠⁠KUKA⁠⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare⁠

Raising capital in Medtech is tougher than ever. Investor expectations have shifted. Competition is up. And many founders are still pitching like it’s 2018.In this episode, Henry Norton sits down with Kiko Filipov, Partner at APPARIUS Corporate Finance and Strategic Advisor at Cruxx, to unpack the real mechanics of a successful fundraise in 2025. From first-in-human data to commercial readiness, Kiko shares what separates the rounds that get oversubscribed from the ones that stall.He also explores the changing landscape of Medtech innovation and why strategic exits take years of planning, how emerging markets are joining the race, and where VCs are placing bets across surgical robotics, neurostimulation, and digital health.Whether you're gearing up for Series A or preparing your pitch deck, this episode delivers tactical clarity from someone who’s in the room with both founders and funds.Key Topics:What VCs actually look for in a Medtech pitchBuilding an equity story that sellsWhy surgical robotics and neurostimulation are hot right nowThe key traits of an acquirable companyCommon reasons fundraises fall flatRelated Insights:Strategic hires matter just as much as the productMarket conditions now demand clearer commercial pathwaysSoftware alone isn't enough, hybrid models are risingInvestors are more risk-averse and selective than everCore Challenges:More competition than ever for VC attentionDelayed investment timing across the boardBurnout risk from unstructured fundraising effortsDifficulties scaling across fragmented EU markets🎧 Tune in now to learn what it really takes to raise and exit in Medtech.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠⁠KUKA⁠⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠⁠kuka.com/healthcare

Join host Henry Norton in this episode of The Crux of Medtech as he speaks to Paul Roberts, co-founder of CMR Surgical and current CEO of Lupin Dental.Paul shares the journey from building surgical robots in a former pig shed to co-founding one of the most recognised names in robotic surgery. Now, he’s applying that experience to an entirely new frontier, aesthetic dental robotics.In this episode, Paul explains why dental veneers are about more than vanity, how robotic precision can eliminate outdated practices like tooth stumping, and why Lupin’s tech could completely transform smile restoration.He also opens up about his medtech philosophy, including why engineers shouldn’t build products alone, and what it really takes to move from zero to launch in a capital-intensive field like robotics.Key TopicsWhy Paul left surgical robotics for dental roboticsThe founding story of CMR SurgicalThe clinical and aesthetic importance of veneersHow Lupin reduces a 5-visit dental process into 1What medtech can learn from AlignTech and InvisalignBuilding a profitable robot company without hundreds of millionsRelated InsightsCrowns are outdated. Robotic veneers restore enamel with less damageEngineers alone don’t make great products clinicians must co-createOne robotic session at Lupin replaces five traditional dental visitsIndia is a strategic first market and a smart regulatory playFail fast, but never compromise on patient safetyCore ChallengesTooth restoration has long been inefficient: dentists rely on hand-guesswork for shaping and prepping teeth. It’s a manual, error-prone process that requires multiple appointments and can cause long-term sensitivity.Lupin Dental solves this with AI-powered planning, CAD design, and a precision robot that prepares the tooth and bonds the veneer all in one session.Tune in now to hear how surgical-grade robotics are reshaping the smile economy and why Lupin Dental could be the next CMR.*The Lupin® Robotic System is not currently approved for clinical use in USA or EU.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠KUKA⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠kuka.com/healthcare

Meet Peter Verrillo, the CEO of Redefine Surgery. He joins your host, Henry Norton, in this episode to discuss the latest developments in orthopaedic AI. Throughout the conversation, Peter highlights how time-consuming knee surgery can be, and talks about the AI solutions that his company is creating to reduce the time spent in theatre. Peter also shares his journey as a founder of multiple different companies, touching on everything from funding and acquisitions to building prototypes in his basement. He also emphasises the benefits of working with device-manufacturing companies, as they will take his AI to market under a whitelabel. He states that this relationship is a key part of the medtech industry. Peter also touches on the importance of strong sales reps, suggesting that they should have training in both the software and robotics sides of this new technology in order to efficiently translate it to surgeons. Key Topics: Peter’s journey from Stryker to founding his own companiesThe benefits of AI-assisted surgical technology The entrepreneurial spirit Redefine Surgery’s vision for the future of orthopaedic proceduresFinding the right people for a medtech team Related Insights: Fully understanding your patient’s problem before incision is key to a quick surgeryAI isn’t a mystical system anymore - it’s a key part of the future of surgery Creating your own team from scratch can be easier than slotting into an existing group Core Challenges:Knee surgery often takes 45 minutes per person due to the need for readjustments once surgeons can see inside the joint. With AI-assisted technology, the time to operate can be brought down to as little as ten minutes thanks to preoperative assessments. Tune in now to find out how orthopaedic surgery will change in the coming years. The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠&⁠⁠KUKA⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠kuka.com/healthcare

Join your host, Henry Norton, and David Caumartin, the CEO of RebrAIn, as they discuss the impact that machine learning and artificial intelligence are having on the clinical outcomes of neurosurgery procedures. During the episode, David shares his medtech story, from how he entered the field to what drew him to RebrAIn several years ago. He also talks about his experience of working with neurosurgeons and how that differs from the other fields he specialised in, such as mammography. David goes on to discuss the benefits of AI in the surgical space, suggesting that it can improve surgeons’ accuracy, patient outcomes and medical research. He also touched on RebrAIn’s clinical trials and the findings that are emerging from them. Key Topics: David’s transition from GE to startupRebrAIn’s unique AI technology The challenges and opportunities within the US marketThe impact of AI on healthcareRelated Insights: AI is making healthcare smarter, faster, and more efficient Collaboration is the key to progress in the healthcare field RebrAIn’s technology can create accurate targets from 100 cases rather than 20,000Core Challenges:The brain is one of the most delicate parts of human anatomy. In order to successfully operate on it, surgeons have to be as precise as possible. Factors like hand tremors, indecision or human error can have a huge impact on patient outcomes.  With an AI assistant, surgeons can assess the best course of action more quickly and accurately. RebrAIn’s AI tool serves as another neurosurgeon in the room. Tune in now to discover the future of neurosurgery. The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠&⁠KUKA⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠kuka.com/healthcare

In this episode, your host, Henry Norton, is joined by Dimitri Sokolov, the CEO at Spiro Robotics, to talk about the limitations of laryngoscopy tools, and what Spiro is doing to remove them. Dimitri explained the difficulties with current intubation methods, as well as the dangers of unsuccessful procedures. He went on to discuss the challenges of getting FDA approval for a new piece of medical robotics. Dimitri also shared some of the adjustments he’s had to make as he moved into the role of CEO, particularly in a small company. This includes growing a team and equipping them to perform at their full capacity. He also shared his story of getting into medical engineering. Key Topics: Dimitri’s path to joining Spiro Robotics The challenges of tracheal intubation Precision-based solutions to medical interventions How robotics can solve staffing shortages Related Insights: The trials of clinical submissions The value of clinical studies and partnerships The opportunities for global advancements Core Challenges:Tracheal intubation is currently difficult for a lot of reasons, and often leads to cancelled surgeries in more troublesome cases. This is an issue for patients, surgeons, and anesthesiologists.  Spiro Robotics have created an intubation solution that enables quicker and more precise procedures, while also removing the need for a second physician in the room. Listen in to this episode to find out more about intubating safely and effectively. The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠&⁠KUKA⁠⁠ is a global leader in robotics with over 25 years of experience partnering with medtech companies on their journey to market. Their reputation is built on robust technology, reliability and long term collaboration and being more than just a supplier.KUKA provides trusted support throughout the product life cycle, from development to integration and beyond. Find out more at ⁠⁠⁠⁠⁠⁠kuka.com/healthcare